Cetero Research Names 25-Year Industry Veteran James Dixon to Head Quality and Compliance

Cary, NC - (April 26, 2011) - Cetero Research, the leading early-stage contract research organization (CRO), today announced the appointment of James "Jay" Dixon to Senior Vice President, Quality and Compliance. Dixon has spent more than 25 years in the pharmaceutical, biotechnology and CRO industries, and will bring his extensive experience to support Cetero's objective of maintaining its market leadership position.

At Cetero, Dixon will lead the Quality and Compliance team, ensuring that Cetero's unwavering commitment to quality provides its clients with the most dependable and accurate results.

"We are thrilled to have someone of Jay's caliber joining the Cetero team," said CEO Troy W. McCall, Ph.D. "Cetero considers quality and compliance to be the utmost priority. Jay's qualifications and background will undoubtedly help raise Cetero's benchmark for quality to an unprecedented new level."

Dixon's career has focused on clinical (GCP), preclinical (GLP), manufacturing (GMP) quality, medical operations and analytical chemistry. Dixon most recently led the quality and compliance efforts for MedImmune, LLC, as Vice President of GxP Quality Compliance. Prior to that, he was at Covance Central Laboratory Services as Vice President of Global Quality Assurance and Business Process Improvement - Six Sigma.

"Quality, safety and consistency are more important than ever in our industry," Dixon said. "I am committed to building upon Cetero's reputation as the leader in early-stage clinical research and to further improving on our record of high-quality performance and reliability."

Prior to his work at Covance, Dixon also held quality-focused leadership positions at Abbott Laboratories, Inc., Triangle Pharmaceuticals (now Gilead Sciences), PAREXEL International Corporation, ClinTrials Research, Inc., Glaxo, Inc. and Glaxo Wellcome, Inc. Dixon holds a bachelor's degree in biology from Campbell University in North Carolina. He is a member of the Board of Directors of Frederick Memorial Healthcare System in Frederick, Maryland, the Drug Information Association (DIA) and the Society of Quality Assurance (SQA).

About Cetero Research
Cetero Research, the leading early-phase contract research organization (CRO), has conducted more than 20,000 clinical pharmacology studies, more than any other CRO. With facilities across North America, Cetero offers flexible, high-quality clinical development services in a range of therapeutic areas, including asthma and allergy, dermatology and diabetes, as well as bioanalytical services to support clinical, preclinical drug and biomarker analysis for small and large molecules. It uses innovative approaches, such as the Accelerated Proof-of-Concept study design to provide key decision-making data earlier in the development process. A pioneer in the pharmaceutical and biotechnology industries, Cetero prioritizes ensuring the safety of its patient and normal healthy study participants, reporting high-quality, reliable data and providing on-time results. For more information, visit www.cetero.com or call 877.7CETERO

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.